Ask VialBase
Dosage Chart

CJC-1295 + Ipamorelin Dosage Chart

CJC-1295 + Ipamorelin dosage chart — per-compound reconstitution, bedtime protocols with exact unit math for each vial, and the no-DAC vs DAC distinction.

Last updated · 2026-08-04
Source this stack
CJC-129512 vetted vendors
BioLongevity LabsVisit BioLongevity Labs →

Save 15% with code VIALBASE

See all 12 sources →
Ipamorelin12 vetted vendors
BioLongevity LabsVisit BioLongevity Labs →

Save 15% with code VIALBASE

See all 12 sources →

VialBase may earn a commission on partner links — never at extra cost to you. Disclosure.

Reconstitution

  • CJC-1295 2 mg / 2 mL — 1,000 mcg/mL (no-DAC / Mod GRF 1-29). On a U-100 syringe, 10 units = 100 mcg.
  • Ipamorelin 5 mg / 2 mL — 2,500 mcg/mL. On a U-100 syringe, 8 units = 200 mcg, 12 units = 300 mcg.

CJC-1295 (no-DAC) and Ipamorelin are reconstituted separately, then drawn into one syringe — they are stable when mixed. Doses below are per compound; the unit marks are for each compound's own vial.

The CJC-1295 + Ipamorelin dosage chart covers per-compound reconstitution and the bedtime protocols below, with the exact unit math for each vial. Unlike a pre-mixed blend, these are two separate peptides — reconstituted individually, then drawn into one syringe — so each tier lists the dose and unit mark for each compound.

Dosage protocols

Starter

Once daily, at bedtime (fasted)
  • CJC-1295 100 mcg · 10 units (0.1 mL)
  • Ipamorelin 200 mcg · 8 units (0.08 mL)
Cycle: 5 days on / 2 days off; reassess at 4 weeks

Entry protocol. Inject at bedtime at least 2 hours after the last meal — GH's largest natural pulse is in early deep sleep, and carbohydrates/insulin blunt the release.

Most common

Standard

Once daily, at bedtime (fasted)
  • CJC-1295 200 mcg · 20 units (0.2 mL)
  • Ipamorelin 300 mcg · 12 units (0.12 mL)
Cycle: 1–3 months on, 2–3 months off; monitor IGF-1 every 4–6 weeks

The common maintenance protocol. CJC-1295 primes the somatotrophs while Ipamorelin fires the release signal — one amplified, natural-shaped pulse. Both draw into the same syringe.

Aggressive (body-composition)

2× daily — AM fasted + PM bedtime
  • CJC-1295 300 mcg · 30 units (0.3 mL)
  • Ipamorelin 300 mcg · 12 units (0.12 mL)
Cycle: 8 weeks max, then 8 weeks off; monitor IGF-1 closely

Higher-output protocol for body-composition goals. The second fasted dose on waking adds another GH pulse. Watch for water retention and paresthesia at this level.

Your vial, your numbers

Different vial size or water volume? Recalculate your exact draw.

CJC-1295

Syringe Size

Draw to mark

20u(0.200 mL)

Concentration

1000 mcg / mL

For research purposes only. Verify all calculations independently before use.

020406080100
20u
100u syringe

Ipamorelin

Syringe Size

Draw to mark

12u(0.120 mL)

Concentration

2500 mcg / mL

For research purposes only. Verify all calculations independently before use.

020406080100
12u
100u syringe

From vial to injection

  1. Sanitize Wipe both peptide vial stoppers and the bacteriostatic-water stopper with fresh alcohol swabs and let them dry.
  2. Reconstitute each vial Add 2 mL bacteriostatic water to the CJC-1295 vial (2 mg) and 2 mL to the Ipamorelin vial (5 mg), letting the water run down the wall of each.
  3. Swirl, don't shake Gently swirl each vial until dissolved. Never shake.
  4. Draw CJC-1295 With a U-100 insulin syringe, draw your CJC-1295 dose (10 units = 100 mcg from the 2 mg / 2 mL vial).
  5. Draw Ipamorelin into the same syringe Without expelling, draw your Ipamorelin dose from its vial (8 units = 200 mcg, 12 units = 300 mcg). The two are stable mixed.
  6. Inject before bed, fasted Inject subcutaneously into the abdomen at least 2 hours after the last meal. Store both reconstituted vials at 2–8 °C and use within 28 days.

Feeling something? Check here

Normal — expected
  • Mild flushing, warmth, or a brief head-rush shortly after injection
  • Transient injection-site redness that fades within an hour
  • Slightly deeper sleep or vivid dreams the first few nights
Back off & reassess
  • Water retention, or tingling/numbness in the hands (paresthesia) — a sign of GH elevation; reduce toward the starter dose
  • Persistent headache or joint stiffness (carpal-tunnel-like) — lower the dose and reassess
  • Injection-site lumps lasting more than a day — rotate sites, check technique
Stop & seek care
  • Facial/throat swelling, difficulty breathing, hives — stop and seek emergency care
  • Signs of injection-site infection — spreading redness, heat, pus, fever
  • Active cancer or tumor history, or uncontrolled diabetes — elevated GH/IGF-1 can promote tumor growth and raises blood glucose; do not use without physician oversight

GH-secretagogue tolerability from the cited literature; ipamorelin selectively releases GH without raising cortisol or prolactin (Raun et al.), and CJC-1295 produced dose-dependent GH/IGF-1 elevation in healthy adults (PMID 16352683).

This self-check is educational, not a diagnosis. When in doubt, stop dosing and consult a qualified healthcare provider.

Frequently Asked Questions

How do you dose CJC-1295 and Ipamorelin together?
Reconstitute each vial separately — CJC-1295 (no-DAC) 2 mg / 2 mL gives 1,000 mcg/mL, Ipamorelin 5 mg / 2 mL gives 2,500 mcg/mL. The standard protocol is 100–300 mcg CJC-1295 plus 200–300 mcg Ipamorelin drawn into one syringe and injected subcutaneously at bedtime, at least 2 hours after eating. On a U-100 syringe, 100 mcg CJC-1295 is 10 units and 300 mcg Ipamorelin is 12 units.
Should I use CJC-1295 with or without DAC?
Most people use CJC-1295 without DAC (Mod GRF 1-29) — its ~30-minute half-life produces a sharp, natural-shaped GH pulse at bedtime. This chart defaults to no-DAC. The DAC version has a ~8-day half-life for sustained elevation from one weekly 2 mg injection (paired with daily Ipamorelin) — more convenient but less physiological.
Why inject at bedtime on an empty stomach?
GH releases its largest natural pulse in early deep sleep, so bedtime dosing aligns with that rhythm. Carbohydrates and insulin blunt GH release, so keep a fasted window of about 2 hours around the injection.
Is the CJC-1295 + Ipamorelin stack FDA-approved?
No. Neither peptide is FDA-approved for these uses, both are research-use-only in the US, and both are prohibited in competitive sport (WADA/USADA). Avoid with active cancer, uncontrolled diabetes, or during pregnancy. Monitor IGF-1 every 4–6 weeks. Community dosing guides are a starting point, not medical advice.

Sources

Full CJC-1295 + Ipamorelin stack profile →